Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alexandria Real Estate Equities, Inc. is a leading REIT focused on the life sciences sector, primarily owning and operating properties in key innovation clusters such as San Francisco, Boston, and San Diego. The company differentiates itself through its specialized facilities designed for biotech and pharmaceutical companies, which require advanced lab space and infrastructure.
Alexandria generates revenue primarily through long-term leases with tenants in the life sciences sector. Its competitive advantage lies in its deep expertise in the life sciences real estate market, allowing it to command premium rents and maintain high occupancy rates. The company also benefits from its strategic locations near top-tier research institutions.
Changes in demand for lab space driven by biotech sector growth
Interest rate fluctuations impacting REIT valuations
Occupancy rates and rental rate growth in key markets
Development pipeline success and lease-up rates
Regulatory changes affecting the life sciences industry
Technological disruption in lab operations or real estate management
Increased competition from other REITs targeting the life sciences sector
Emergence of alternative workspaces that could reduce demand for traditional lab space
High debt levels relative to equity could pressure cash flows during downturns
Liquidity risks due to low current ratio of 0.29
moderate - the demand for life sciences real estate is somewhat insulated from economic downturns, but overall growth is linked to broader economic conditions and funding in the biotech sector.
Higher interest rates increase borrowing costs for development projects and can compress REIT valuations as investors seek higher yields elsewhere. This could lead to reduced demand for new leases.
minimal - Alexandria's business model is not heavily reliant on credit, but higher interest rates could impact its cost of capital.
growth - investors are drawn to Alexandria for its potential upside linked to the expanding life sciences sector.
moderate - the stock has shown significant price fluctuations, evidenced by a 39.4% decline over the past year.